CTBP2, C-terminal binding protein 2, 1488

N. diseases: 62; N. variants: 13
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.160 GeneticVariation disease GWASCAT Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 29892016 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.160 Biomarker disease BEFREE Antimony enhances c-Myc stability in prostate cancer via activating CtBP2-ROCK1 signaling pathway. 30098506 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.160 Biomarker disease BEFREE These results highlight the association between CtBP2 and angiogenesis in PCa and indicate that CtBP2 may be a potential therapeutic target for PCa. 28677795 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.160 Biomarker disease BEFREE Taken together, our investigations demonstrated that low-expression of CtBP2 could highly inhibit proliferation of prostate cancer by c-Myc induced signaling, suggesting that targeting CtBP2 may yield a viable anti-tumor strategy by restraining tumor progression in prostate cancer. 24835310 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.160 Biomarker disease BEFREE Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression. 24332637 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.160 Biomarker disease BEFREE Overall, our results show how CtBP2 contributes to prostate cancer progression by modulating AR and oncogenic signaling. 25228652 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.160 GeneticVariation disease BEFREE After allowing for multiple testing, none of the SNPs examined were significantly associated with growth factor or hormone concentrations, and the SNP-prostate cancer associations did not differ by these concentrations, although 4 interactions were marginally significant (MSMB-rs10993994 with androstenedione (uncorrected P = 0.008); CTBP2-rs4962416 with IGFBP-3 (uncorrected P = 0.003); 11q13.2-rs12418451 with IGF-1 (uncorrected P = 0.006); and 11q13.2-rs10896449 with SHBG (uncorrected P = 0.005)). 22459122 2012
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.160 GeneticVariation disease GWASCAT Multiple loci identified in a genome-wide association study of prostate cancer. 18264096 2008